Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
暂无分享,去创建一个
R. Lo | G. Moriceau | Jun Wu | Ying Yang | M. A. Reid | Thai Q. Tran | X. Lowman | Mei Kong | Jenny E. Hernandez-Davies | K. Rosales | Min Pan
[1] A. Ribas,et al. Anti-PD-1 therapy in melanoma. , 2015, Seminars in oncology.
[2] P. Queirolo,et al. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. , 2015, Cancer treatment reviews.
[3] J. Larkin,et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.
[4] P. Queirolo,et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies , 2015, OncoTargets and therapy.
[5] J. Rasko,et al. Targeting glutamine transport to suppress melanoma cell growth , 2014, International journal of cancer.
[6] A. Ribas,et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. , 2014, The Lancet. Oncology.
[7] Jason Li,et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.
[8] Dirk Schadendorf,et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.
[9] A. Bucheit,et al. Emerging insights into resistance to BRAF inhibitors in melanoma. , 2014, Biochemical pharmacology.
[10] K. Thangavelu,et al. Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA) , 2014, Scientific Reports.
[11] P. Ascierto,et al. Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study , 2013, Cancer investigation.
[12] John M. Asara,et al. Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.
[13] C. Dang,et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. , 2012, Journal of medicinal chemistry.
[14] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[15] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[16] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[17] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[18] K. Thangavelu,et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism , 2012, Proceedings of the National Academy of Sciences.
[19] Takashi Tsukamoto,et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.
[20] A. Ribas,et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.
[21] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[22] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[23] G. Riggins,et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.
[24] C. Thompson,et al. Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.
[25] Paul S Mischel,et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.
[26] R. Deberardinis,et al. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.
[27] N. Curthoys,et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). , 2007, The Biochemical journal.
[28] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[29] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[30] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[31] C. Reynolds,et al. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. , 2005, Methods in molecular medicine.
[32] F. Muggia,et al. The rediscovery of DON (6-diazo-5-oxo-L-norleucine). , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[33] E. Casper,et al. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). , 1980, Cancer treatment reports.